MedStar Authors catalog › Details for: Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
Normal view MARC view ISBD view

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.

by Swain, Sandra M; Zapas, John L.
Citation: Journal of Clinical Oncology. 35(35):3942-3948, 2017 Dec 10.Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology.Published: 2017ISSN: 0732-183X.Full author list: Ganz PA; Romond EH; Cecchini RS; Rastogi P; Geyer CE Jr; Swain SM; Jeong JH; Fehrenbacher L; Gross HM; Brufsky AM; Flynn PJ; Wahl TA; Seay TE; Wade JL 3rd; Biggs DD; Atkins JN; Polikoff J; Zapas JL; Mamounas EP; Wolmark N.UI/PMID: 29072977.Subject(s): *Antineoplastic Combined Chemotherapy Protocols/ad [Administration & Dosage] | Antineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects] | *Breast Neoplasms/dt [Drug Therapy] | Breast Neoplasms/en [Enzymology] | Breast Neoplasms/pa [Pathology] | *Breast Neoplasms/pp [Physiopathology] | *Cardiovascular System/pp [Physiopathology] | Chemotherapy, Adjuvant | Cohort Studies | Cyclophosphamide/ad [Administration & Dosage] | Cyclophosphamide/ae [Adverse Effects] | Doxorubicin/ad [Administration & Dosage] | Doxorubicin/ae [Adverse Effects] | Female | Follow-Up Studies | Humans | Lymphatic Metastasis | Middle Aged | Paclitaxel/ad [Administration & Dosage] | Paclitaxel/ae [Adverse Effects] | Quality of Life | *Receptor, ErbB-2/bi [Biosynthesis] | Trastuzumab/ad [Administration & Dosage] | Trastuzumab/ae [Adverse Effects] | Ventricular Dysfunction, Left/pp [Physiopathology]Institution(s): Washington Cancer InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1200/JCO.2017.74.1165 (Click here) Abbreviated citation: J Clin Oncol. 35(35):3942-3948, 2017 Dec 10.Local Holdings: Available online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008.Abstract: Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of patients who remain cancer free after completion of adjuvant treatment. Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer. A long-term follow-up assessment was undertaken for patients who were alive and disease free, which included measurement of left ventricular ejection fraction by multigated acquisition scan along with patient-reported outcomes using the Duke Activity Status Index (DASI), the Medical Outcomes Study questionnaire, and a review of current medications and comorbid conditions. Results At a median follow-up of 8.8 years among eligible participants, five (4.5%) of 110 in the control group and 10 (3.4%) of 297 in the trastuzumab group had a > 10% decline in left ventricular ejection fraction from baseline to a value < 50%. Lower DASI scores correlated with age and use of medications for hypertension, cardiac conditions, diabetes, and hyperlipidemia, but not with whether patients had received trastuzumab. Conclusion In patients without underlying cardiac disease at baseline, the addition of trastuzumab to adjuvant anthracycline and taxane-based chemotherapy does not result in long-term worsening of cardiac function, cardiac symptoms, or health-related quality of life. The DASI questionnaire may provide a simple and useful tool for monitoring patient-reported changes that reflect cardiac function.

Powered by Koha